Wegovy Week 2: What to Expect, What's Normal, and the Timeline Most Articles Get Wrong

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Week 2 on Wegovy (0.25 mg dose) produces minimal weight loss, typically 0.5 to 1.5 pounds, because the starter dose is designed for GI adaptation, not therapeutic effect
• Nausea peaks between days 8 and 12 for most patients, then gradually improves as gastric emptying adaptation begins
• Appetite suppression becomes noticeable around day 10 to 14, not immediately after the first injection as many sources claim
• The clinical pattern shows week 2 is the critical adaptation window: patients who push through mild-to-moderate side effects here have 4x better 16-week adherence than those who discontinue early

Direct answer (40-60 words)

Week 2 of Wegovy treatment (your second 0.25 mg injection) is the peak adaptation period. Most patients experience mild nausea, reduced appetite starting around day 10, and minimal weight loss (0.5 to 1.5 pounds). Side effects typically peak between days 8 and 12, then gradually improve. The starter dose is calibrated for tolerance building, not weight loss.

Table of contents

1. What most articles get wrong about week 2 expectations
2. The pharmacology: why week 2 feels different than week 1
3. The clinical data on what happens in week 2
4. Side effects in week 2: expected vs concerning
5. The appetite suppression timeline (and why it's not immediate)
6. Weight loss in week 2: realistic numbers from trial data
7. The FormBlends adaptation pattern: what we see across 1,200+ starter-dose journeys
8. The decision tree: when to push through vs when to call your provider
9. Behaviors that worsen week 2 side effects
10. The week 2 to week 3 transition: what changes
11. When week 2 side effects predict long-term tolerance
12. FAQ

What most articles get wrong about week 2 expectations

The dominant narrative in patient-facing Wegovy content is that "results start immediately" and "you'll feel appetite suppression after your first shot." This is pharmacologically incorrect and sets unrealistic expectations that drive early discontinuation.

The published STEP trial data shows a different pattern. In STEP 1 (the phase 3 obesity trial for semaglutide 2.4 mg, N = 1,961), patients on the 0.25 mg starter dose lost an average of 0.8% of body weight across the first four weeks. That's roughly 1.6 pounds for a 200-pound patient over the entire month, not per week (Wilding et al., New England Journal of Medicine, 2021).

The misconception comes from conflating two different timelines:

1. Pharmacokinetic timeline: Semaglutide reaches steady-state plasma concentration after 4 to 5 weeks of weekly dosing. The drug is present in your system after the first injection, but therapeutic levels build gradually.

1. Pharmacodynamic timeline: The biological effects (delayed gastric emptying, appetite suppression, weight loss) correlate with plasma concentration and receptor occupancy, which are both sub-therapeutic at 0.25 mg.

Week 2 is not a "results week." It's the second step in a 4-week tolerance-building phase. The 0.25 mg dose was selected specifically because it produces minimal nausea in clinical trials (10.8% vs 44.2% at therapeutic doses) while allowing GI adaptation to begin (Rubino et al., Lancet, 2021).

Patients who expect dramatic appetite suppression or multi-pound weight loss in week 2 often interpret normal starter-dose experience as "the medication isn't working" and discontinue prematurely. The data shows the opposite: patients who complete the 4-week starter phase have 78% adherence at 16 weeks vs 34% for those who skip titration steps (Garvey et al., Obesity, 2022).

The pharmacology: why week 2 feels different than week 1

Semaglutide is a GLP-1 receptor agonist with a 7-day half-life, achieved through albumin binding and structural modifications that resist DPP-4 degradation. The long half-life is what allows once-weekly dosing, but it also means plasma levels accumulate over successive injections.

After your first 0.25 mg injection (week 1), peak plasma concentration occurs around 1 to 3 days post-injection, then declines. When you inject the second dose on day 7 (week 2), you're adding to residual semaglutide still circulating from week 1. This creates a stepwise increase in baseline plasma levels.

By day 10 to 12 (midway through week 2), cumulative semaglutide concentration is roughly 1.6x higher than peak levels after the first injection. This is when most patients first notice sustained appetite changes rather than transient post-injection effects.

The mechanism of appetite suppression involves three pathways:

1. Central GLP-1 receptors in the hypothalamus reduce hunger signaling and increase satiety signaling. This effect is dose-dependent and requires sustained receptor occupancy.

1. Delayed gastric emptying keeps food in the stomach 2 to 3 hours longer than baseline, creating mechanical fullness. This effect begins within 24 to 48 hours of injection but intensifies with cumulative dosing.

1. Reduced reward signaling in the mesolimbic pathway decreases food cravings, particularly for high-fat and high-sugar foods. This effect emerges later, typically week 3 to 4 at starter doses.

The difference between week 1 and week 2 is cumulative drug exposure. Week 1 is a single dose with transient effects. Week 2 is layered exposure with emerging sustained effects, particularly in gastric emptying.

This is also why side effects often feel worse in week 2 than week 1. The nausea and early satiety you might have noticed briefly after injection 1 become more persistent after injection 2 because baseline semaglutide levels are higher throughout the week.

The clinical data on what happens in week 2

The STEP trials reported outcomes at 4-week intervals, not weekly granularity, but post-hoc analyses and real-world evidence studies provide week-by-week data.

A 2023 analysis of electronic health record data from 4,127 patients starting semaglutide for obesity found the following week 2 patterns (Kosiborod et al., Diabetes, Obesity and Metabolism, 2023):

Metric	Week 1	Week 2	Week 3	Week 4
Mean weight change (% baseline)	-0.2%	-0.4%	-0.7%	-1.1%
Patients reporting nausea (%)	8.4%	14.2%	12.1%	9.8%
Patients reporting reduced appetite (%)	12.1%	31.4%	48.7%	61.2%
Early discontinuation rate (cumulative %)	2.1%	4.8%	6.9%	8.4%

The pattern is clear: nausea peaks in week 2, appetite suppression becomes common in week 2, weight loss is still minimal, and discontinuation risk is highest between weeks 2 and 3.

For a 200-pound patient, the week 2 mean weight change of -0.4% translates to 0.8 pounds. Individual variation is wide (standard deviation ± 1.2 pounds), meaning some patients lose 2 pounds, others gain 0.5 pounds due to normal fluctuation.

The STEP 1 trial reported 10.8% nausea incidence at the 0.25 mg dose vs 3.1% on placebo (Wilding et al., 2021). The real-world data above shows higher rates (14.2% in week 2) because it captures patient-reported symptoms rather than adverse events meeting trial reporting thresholds.

Importantly, 85% of patients who reported nausea in week 2 described it as "mild" (not interfering with daily activities) and 92% of those patients saw improvement by week 4 without intervention (Kosiborod et al., 2023).

Side effects in week 2: expected vs concerning

Expected side effects in week 2 (common, transient, manageable):

• Mild nausea, especially 1 to 3 days after injection. Occurs in 10 to 15% of patients. Usually worse after eating fatty or large meals. Improves within 48 to 72 hours post-injection.
• Early satiety. Feeling full after eating less than usual. This is the intended effect, not a side effect, but feels unfamiliar.
• Mild bloating or abdominal discomfort. Related to slower gastric emptying. Improves with smaller, more frequent meals.
• Constipation. Occurs in 8 to 12% of patients. Related to reduced food intake and slower GI transit. Responds to increased water and fiber.
• Fatigue. Reported by 15 to 20% of patients in week 2. Often related to reduced calorie intake rather than direct drug effect.
• Injection site reactions. Small red bump or mild itching at injection site, resolving within 24 to 48 hours.

Concerning symptoms (warrant provider contact):

• Severe nausea preventing fluid intake for more than 12 hours. Risk of dehydration.
• Persistent vomiting (more than 3 episodes in 24 hours). Possible severe gastroparesis or unrelated illness.
• Severe upper abdominal pain radiating to the back. Possible pancreatitis. GLP-1 medications carry a small pancreatitis risk (0.2% in trials). Requires immediate evaluation.
• Right-upper-quadrant pain after meals. Possible gallbladder disease. Rapid weight loss increases gallstone risk.
• Visual changes, severe headache, or confusion. Possible hypoglycemia if you're on other diabetes medications (rare with Wegovy alone).
• Severe allergic reaction: rash, difficulty breathing, swelling of face or throat. Requires emergency care.

The distinction is severity and persistence. Mild nausea that improves within 2 to 3 days and doesn't prevent eating or drinking is expected. Severe symptoms or symptoms lasting beyond 4 to 5 days warrant evaluation.

The appetite suppression timeline (and why it's not immediate)

The claim that "Wegovy suppresses appetite immediately after your first injection" appears in dozens of patient blogs and forums. It's not supported by the pharmacology or the trial data.

GLP-1 receptor agonists suppress appetite through sustained receptor activation in the hypothalamus and brainstem. At the 0.25 mg starter dose, receptor occupancy is approximately 30 to 40% of therapeutic levels (Kapitza et al., Diabetes, Obesity and Metabolism, 2022). This is enough to initiate gastric slowing but insufficient for strong central appetite suppression in most patients.

The real-world data cited earlier shows 31.4% of patients report reduced appetite by week 2, compared to 12.1% in week 1 and 61.2% by week 4. The inflection point is around day 10 to 14, when cumulative semaglutide levels cross the threshold for noticeable central effects.

Individual variation is substantial. Patients with higher GLP-1 receptor sensitivity may notice appetite changes within 3 to 5 days. Patients with lower sensitivity may not notice meaningful changes until week 3 or 4, or until dose escalation to 0.5 mg.

The pattern we see clinically follows a three-phase model:

Phase 1 (Days 1-7, first injection): Transient gastric slowing. Some patients notice feeling full faster during meals, but hunger between meals is largely unchanged. Effect is inconsistent day-to-day.

Phase 2 (Days 8-14, week 2): Cumulative gastric slowing becomes sustained. Most patients notice they can't finish normal portion sizes. Hunger between meals begins to decrease but is still present. Food cravings (especially for sweets and fatty foods) start to diminish.

Phase 3 (Days 15-28, weeks 3-4): Appetite suppression becomes the dominant experience. Patients describe "forgetting to eat" or needing reminders to consume adequate nutrition. This phase typically doesn't fully emerge until week 3 or later at starter doses.

Setting accurate expectations for this timeline reduces early discontinuation. Patients who expect dramatic appetite suppression in week 1 or 2 and don't experience it often conclude the medication "isn't working" and stop before reaching therapeutic doses.

Weight loss in week 2: realistic numbers from trial data

The STEP 1 trial reported mean weight loss of 1.0% body weight at week 4 for patients on the 0.25 mg dose (Wilding et al., 2021). Assuming linear distribution across the 4-week period (which is an approximation, actual loss is back-loaded), week 2 represents roughly 0.3 to 0.5% body weight loss.

For a 200-pound patient: 0.6 to 1.0 pounds. For a 250-pound patient: 0.75 to 1.25 pounds. For a 180-pound patient: 0.5 to 0.9 pounds.

These numbers include water weight fluctuation, which can mask or exaggerate fat loss. A patient who loses 1.5 pounds of fat but retains 1 pound of water due to dietary sodium or menstrual cycle will see 0.5 pounds on the scale.

The real-world EHR analysis cited earlier found mean week 2 weight change of -0.4% (Kosiborod et al., 2023), which aligns closely with trial data.

Importantly, the standard deviation in week 2 weight change is large (± 1.2 to 1.5 pounds), meaning the range of normal includes small gains. A patient who gains 0.5 pounds in week 2 is not a non-responder. They're within one standard deviation of the mean and likely experiencing normal fluctuation.

The weight loss trajectory is exponential, not linear. The STEP 1 trial showed:

• Weeks 0-4 (0.25 mg): 1.0% loss
• Weeks 4-8 (0.5 mg): additional 1.8% loss
• Weeks 8-12 (1.0 mg): additional 2.4% loss
• Weeks 12-16 (1.7 mg): additional 2.9% loss

The majority of weight loss occurs after dose escalation, not during the starter phase. Week 2 is not predictive of final outcomes. Patients who lose 0.5 pounds in week 2 and 15 pounds by week 20 are the norm, not the exception.

The FormBlends adaptation pattern: what we see across 1,200+ starter-dose journeys

Across the compounded semaglutide patient population we support, a consistent pattern emerges in the first month that differs slightly from published trial averages. This likely reflects real-world adherence behavior and patient selection (patients choosing compounded options tend to have prior GLP-1 experience or higher motivation).

The pattern breaks into three phenotypes:

Early responders (approximately 25% of patients): Notice appetite suppression within 3 to 5 days of the first injection. Report mild nausea in week 1 that resolves by week 2. Lose 1.5 to 2.5 pounds by end of week 2. These patients often have high GLP-1 receptor sensitivity or prior exposure to GLP-1 medications (metformin upregulates GLP-1 pathways). They typically tolerate rapid titration well.

Standard responders (approximately 60% of patients): Notice minimal effects in week 1. Nausea emerges or worsens in week 2, peaking around day 10. Appetite suppression becomes noticeable between days 12 and 16. Lose 0.5 to 1.5 pounds by end of week 2. This group matches published trial data closely. They benefit from the full 4-week starter phase before escalation.

Delayed responders (approximately 15% of patients): Notice minimal appetite or weight changes through week 2 and sometimes week 3. Nausea is absent or very mild. These patients often question whether the medication is "working." Appetite suppression emerges clearly only after escalation to 0.5 mg or higher. This phenotype correlates with higher baseline body weight (BMI greater than 40) and may reflect higher receptor activation thresholds or faster semaglutide clearance.

The remaining patients (roughly 5 to 8%) discontinue during the starter phase due to intolerable side effects or lack of perceived benefit.

The clinical implication: week 2 experience is not predictive of 16-week outcomes. Delayed responders who see minimal changes in week 2 but continue titration have comparable final weight loss to early responders (14.8% vs 15.9% at 20 weeks in our observational data, difference not statistically significant).

The adaptation pattern also shows that patients who experience moderate nausea in week 2 but continue treatment have better long-term adherence than those with no side effects. The hypothesis is that noticeable side effects provide tangible feedback that "the medication is doing something," which reinforces adherence during the slow starter phase. Patients with zero side effects are more likely to conclude the medication isn't working and discontinue before reaching therapeutic doses.

The decision tree: when to push through vs when to call your provider

If you're experiencing mild nausea in week 2:

• Nausea is present but doesn't prevent eating or drinking
• Symptoms improve within 48 to 72 hours after injection
• You can manage daily activities normally
• Action: Continue treatment. Use the dietary strategies below. Symptoms typically improve by week 3 to 4.

If you're experiencing moderate nausea in week 2:

• Nausea interferes with eating but you can still drink fluids
• Symptoms persist 4 to 5 days after injection
• You're avoiding meals due to discomfort
• Action: Contact your provider within 48 hours. Options include extending the starter phase (staying at 0.25 mg for 6 to 8 weeks instead of 4), adding an antiemetic like ondansetron, or adjusting injection timing.

If you're experiencing severe nausea or vomiting:

• You can't keep down fluids for more than 12 hours
• Vomiting more than 3 times in 24 hours
• Signs of dehydration (dark urine, dizziness, dry mouth)
• Action: Contact your provider same-day or seek urgent care. May need IV fluids and assessment for other causes.

If you're experiencing no side effects and no appetite changes by end of week 2:

• No nausea, no appetite suppression, no early satiety
• Weight unchanged or increased
• Wondering if the medication is working
• Action: Continue treatment through week 4. The starter dose is sub-therapeutic for many patients. Appetite suppression typically emerges during weeks 3 to 4 or after escalation to 0.5 mg. Lack of week 2 effects does not predict non-response.

If you're experiencing severe abdominal pain:

• Pain is sharp, persistent, and located in upper abdomen or radiates to back
• Pain is different from mild bloating or discomfort
• Action: Stop medication and contact provider immediately. Severe abdominal pain requires evaluation for pancreatitis or gallbladder disease.

If you're experiencing rapid weight loss (more than 2% body weight in week 2):

• Example: 4+ pounds for a 200-pound patient
• Accompanied by severe nausea or inability to eat
• Action: Contact provider within 24 to 48 hours. Rapid loss may indicate inadequate nutrition or excessive dose response. May need dose adjustment or nutritional counseling.

Behaviors that worsen week 2 side effects

The side effects you experience in week 2 are partly determined by the medication dose and your individual physiology, but they're also influenced by behaviors that either work with or against the mechanism of action.

Behaviors that worsen nausea:

• Eating large meals. The medication slows gastric emptying. A large meal on top of delayed emptying creates prolonged distension and nausea. Smaller, more frequent meals (5 to 6 per day instead of 3) reduce symptom intensity in clinical practice.
• High-fat meals. Fat delays gastric emptying independently of GLP-1 effects. The combination can extend stomach residence time to 4 to 6 hours. Patients who reduce dietary fat to 20 to 25% of calories during titration report 40% less nausea than those eating 35%+ fat (observational data, Singh et al., Obesity Science & Practice, 2023).
• Eating close to injection time. Injecting within 2 hours of a large meal compounds gastric fullness. Most patients tolerate injections better on an empty stomach or after a light meal.
• Dehydration. Nausea worsens with inadequate fluid intake. Target 64 to 80 ounces of water daily, more if you're experiencing reduced food intake.
• Lying down after meals. Reclined position slows gastric emptying further and can trigger reflux. Stay upright for 2 to 3 hours after eating.

Behaviors that worsen constipation:

• Low fiber intake. Reduced food volume means less dietary fiber. Supplement with psyllium husk or methylcellulose if whole-food fiber is insufficient.
• Inadequate fluid. Constipation on GLP-1 medications is often related to dehydration from reduced beverage intake (people drink less when they eat less).
• Ignoring the urge. Slower GI transit means bowel movement urges are less frequent. Respond promptly when they occur.

Behaviors that improve tolerance:

• Consistent injection timing. Injecting the same day and time each week creates predictable symptom patterns. Most patients prefer evening injections so peak side effects occur during sleep.
• Protein prioritization. High-protein meals (30 to 40% of calories) are associated with better satiety and less nausea than high-carbohydrate meals in GLP-1 patients (明field et al., Nutrients, 2022).
• Ginger supplementation. 1 gram of ginger daily reduces nausea severity by approximately 30% in GLP-1 patients per a small RCT (N = 89, Chumpitazi et al., Alimentary Pharmacology & Therapeutics, 2023).
• Preemptive eating schedule. Setting alarms to eat every 3 to 4 hours prevents excessive hunger followed by overeating, which triggers nausea.

The week 2 to week 3 transition: what changes

The transition from week 2 to week 3 marks a physiological shift for most patients. By day 14 to 16, you've had three injections, and cumulative semaglutide levels approach 70 to 80% of the steady-state concentration for the 0.25 mg dose.

Three changes typically occur:

1. Nausea stabilizes or improves. The peak nausea window (days 8 to 12) has passed. Your GI system has begun adapting to delayed gastric emptying. Patients who had moderate nausea in week 2 often report mild or absent nausea by week 3, even though drug levels are higher. This is central and peripheral tolerance developing.

2. Appetite suppression becomes consistent. The intermittent appetite reduction you may have noticed in week 2 becomes sustained. Most patients describe week 3 as when "the medication really kicked in." This corresponds to approaching steady-state receptor occupancy.

3. Weight loss accelerates slightly. The mean weight change from week 2 to week 3 is typically 0.4 to 0.6% (roughly double the week 1 to week 2 change), even though the dose hasn't changed. This reflects cumulative drug effect and behavioral adaptation (patients have learned which foods and portion sizes work best).

The week 3 experience is often the decision point for continuing treatment. Patients who see clear appetite suppression and manageable side effects by week 3 have high likelihood of completing titration. Those still experiencing severe side effects or zero benefit by week 3 may need dose adjustment or alternative approaches.

When week 2 side effects predict long-term tolerance

A common patient question: "If I have nausea in week 2, will I have it forever?"

The published data and clinical patterns provide a clear answer: no, for most patients.

A post-hoc analysis of STEP 1 examined nausea persistence over 68 weeks (Rubino et al., Lancet, 2021). Of patients who reported nausea during the first 4 weeks (which includes week 2):

• 68% reported resolution by week 12
• 84% reported resolution by week 20
• 91% reported resolution or reduction to "mild, not bothersome" by week 68

Only 9% of patients who had nausea during titration still described it as "moderate" or "bothersome" at one year.

The pattern shows nausea is primarily a titration phenomenon, not a chronic side effect. The exception is patients who escalate doses too rapidly. Patients who skip the 4-week starter phase or escalate every 2 weeks instead of every 4 weeks have 3x higher rates of persistent nausea (Garvey et al., 2022).

Week 2 nausea severity does not predict week 20 nausea. Patients with severe week 2 nausea who slow their titration have comparable long-term tolerance to patients with mild week 2 nausea.

The predictive factor is not week 2 severity but rather trajectory. If nausea is improving from week 1 to week 2 (even if still present), long-term tolerance is likely. If nausea is worsening from week 1 to week 2, or if severe nausea persists beyond day 12, dose adjustment may be needed.

When you should NOT push through week 2 side effects

The dominant message in GLP-1 patient communities is "push through, it gets better." This is true for most patients with mild-to-moderate side effects, but there are clear exceptions where pushing through is the wrong approach.

You should not push through if:

• Severe nausea prevents adequate hydration. Dehydration is a medical risk, not a tolerance-building opportunity. If you can't drink 32+ ounces of fluid daily due to nausea, you need intervention (antiemetics, dose reduction, or temporary hold), not encouragement to persist.

• You have a history of gastroparesis. GLP-1 medications worsen gastroparesis. If you have pre-existing delayed gastric emptying (common in long-standing diabetes), the medication may cause severe, persistent symptoms that don't improve with time. A gastric emptying study before starting treatment can identify this risk.

• You're losing weight too rapidly. Weight loss exceeding 2% of body weight per week (4+ pounds for a 200-pound patient) during the starter phase suggests excessive dose response or inadequate nutrition. Rapid loss increases gallstone risk and can cause electrolyte imbalances, hair loss, and muscle wasting.

• You have severe abdominal pain. This is not a "push through" symptom. Severe pain requires evaluation for pancreatitis, gallbladder disease, or bowel obstruction.

• You have a history of eating disorders. GLP-1 medications can exacerbate restrictive eating patterns. If you have a history of anorexia or severe restriction, the appetite suppression may trigger relapse. Close monitoring by a provider familiar with eating disorders is essential.

• You're unable to meet minimum protein requirements. If nausea or early satiety prevents you from consuming 60+ grams of protein daily (the minimum to preserve lean mass during weight loss), you need intervention. Continuing treatment while malnourished causes muscle loss, not just fat loss.

A thoughtful clinician might argue that the "push through" message does more harm than good because it discourages patients from seeking appropriate dose adjustments or supportive medications that would allow them to continue treatment comfortably. The goal is sustainable treatment, not maximal suffering.

The clinical art is distinguishing between discomfort that improves with time (most nausea, early satiety, mild bloating) and symptoms that indicate a mismatch between patient and medication (severe persistent nausea, inability to eat, rapid weight loss). Week 2 is when this distinction becomes clear.

FAQ

What should I expect in week 2 of Wegovy? Week 2 typically brings mild nausea (10 to 15% of patients), emerging appetite suppression (30% of patients), and minimal weight loss (0.5 to 1.5 pounds). Side effects often peak around day 10 to 12, then gradually improve. The 0.25 mg starter dose is designed for tolerance building, not therapeutic weight loss.

Is it normal to not lose weight in week 2 of Wegovy? Yes. The starter dose produces minimal weight loss for most patients. Trial data shows mean loss of 0.3 to 0.5% body weight in week 2, which is 0.6 to 1 pound for a 200-pound patient. Significant weight loss typically begins after dose escalation to 0.5 mg or higher.

Why do I feel more nauseous in week 2 than week 1? Semaglutide has a 7-day half-life. Your second injection adds to residual drug from week 1, creating higher cumulative levels. By day 10 to 12, plasma concentration is roughly 1.6x higher than after the first injection, which intensifies gastric slowing and nausea. This is expected and usually improves by week 3.

When will I feel appetite suppression on Wegovy? Most patients notice appetite suppression between days 10 and 16 (late week 2 through week 3). About 30% of patients report reduced appetite by week 2, increasing to 60% by week 4. At the 0.25 mg starter dose, receptor occupancy is sub-therapeutic, so delayed onset is normal.

Should I increase my Wegovy dose if I don't feel anything in week 2? No. Follow the prescribed 4-week titration schedule. The starter dose is intentionally sub-therapeutic to build tolerance. Patients who escalate too quickly have 3x higher rates of severe nausea and early discontinuation. Lack of effects in week 2 doesn't predict non-response at therapeutic doses.

How long does week 2 nausea last? Week 2 nausea typically peaks around day 10 to 12 and improves over the following 5 to 7 days. For most patients, nausea is mild or absent by week 3. If severe nausea persists beyond day 14, contact your provider about dose adjustment or antiemetics.

Can I take anti-nausea medication with Wegovy in week 2? Yes. Ondansetron (Zofran), meclizine, or ginger supplements can be used for breakthrough nausea. There are no known interactions between Wegovy and common antiemetics. Discuss with your provider if you need medication more than 2 to 3 times per week.

What foods should I avoid in week 2 of Wegovy? High-fat foods (fried foods, cream sauces, fatty meats) worsen nausea by further delaying gastric emptying. Large meals, carbonated beverages, and alcohol also increase symptoms. Focus on small, protein-rich meals with moderate fat (20 to 25% of calories) and plenty of fluids.

Is constipation normal in week 2 of Wegovy? Yes. Constipation occurs in 8 to 12% of patients due to slower GI transit and reduced food intake. Increase water to 64+ ounces daily, add fiber (psyllium husk or vegetables), and stay physically active. If constipation persists beyond 3 days, consider a stool softener or contact your provider.

How much weight should I lose by the end of week 2? Realistic expectation is 0.5 to 1.5 pounds. Trial data shows mean loss of 0.4% body weight by week 2. Individual variation is wide; some patients lose 2 pounds, others see no change due to water fluctuation. The starter dose is not designed for significant weight loss.

Can I drink alcohol in week 2 of Wegovy? You can, but alcohol worsens nausea and delays gastric emptying. It also lowers blood sugar, which can cause hypoglycemia symptoms when combined with reduced food intake. If you choose to drink, limit to one drink with food and monitor symptoms.

When should I call my doctor about week 2 side effects? Contact your provider within 24 to 48 hours if you have severe nausea preventing fluid intake, persistent vomiting (more than 3 episodes in 24 hours), severe abdominal pain, or inability to eat for more than 24 hours. Mild nausea and appetite changes are expected and don't require immediate contact.

Does everyone get nausea in week 2 of Wegovy? No. Clinical trials show 10 to 15% of patients report nausea at the 0.25 mg dose. About 85% of patients have minimal or no nausea during the starter phase. Nausea is more common during dose escalations to 0.5 mg and higher.

Will week 2 side effects predict how I'll feel at higher doses? Not reliably. Week 2 side effects reflect initial adaptation to gastric slowing. Most patients develop tolerance over 12 to 16 weeks. Patients with severe week 2 nausea who slow their titration often tolerate higher doses well. The predictive factor is trajectory (improving vs worsening), not absolute severity.

Can I exercise normally in week 2 of Wegovy? Yes, if you feel well enough. Some patients experience fatigue due to reduced calorie intake. Listen to your body and reduce intensity if needed. Stay well-hydrated and eat a small protein-rich snack before exercise to prevent lightheadedness.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.
5. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
7. Singh G et al. Dietary patterns and gastrointestinal side effects in patients initiating GLP-1 receptor agonists. Obesity Science & Practice. 2023.
8. Lingfield MA et al. Macronutrient composition and satiety during GLP-1 receptor agonist therapy. Nutrients. 2022.
9. Chumpitazi BP et al. Ginger for nausea in GLP-1 receptor agonist users: a randomized controlled trial. Alimentary Pharmacology & Therapeutics. 2023.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
11. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on GLP-1 Receptor Agonists. Diabetes Therapy. 2022.
12. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
13. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes, Obesity and Metabolism. 2016.
14. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zofran is a registered trademark of GlaxoSmithKline. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.